Stefanie Hayoz
Papers
1
Total Citations
32
H-Index
1
About
Stefanie Hayoz is a leading clinical researcher in urothelial carcinoma, with a primary focus on improving treatment outcomes for muscle-invasive bladder cancer through innovative perioperative strategies. Her most impactful work centers on integrating immunotherapy with standard chemotherapy regimens to reduce relapse rates following surgery. In her landmark phase II trial (SAKK 06/17), Hayoz investigated the combination of durvalumab with cisplatin/gemcitabine as neoadjuvant therapy for operable muscle-invasive urothelial carcinoma. The preplanned interim analysis of this single-arm study, which has garnered 32 citations, provided critical early evidence that combining checkpoint inhibition with chemotherapy is both feasible and potentially more effective than chemotherapy alone in the perioperative setting. This work addresses a key unmet need, as relapse rates remain high despite standard cisplatin-based neoadjuvant chemotherapy. By demonstrating the safety and preliminary efficacy of this chemoimmunotherapy approach, Hayoz has helped pave the way for larger randomized trials and has contributed to the evolving paradigm of incorporating immune checkpoint inhibitors earlier in the treatment course for bladder cancer patients.
Research Focus
Key Achievements
Top Papers
- 1